Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
thoracic radiotherapy · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| thoracic radiotherapy | RADIATION | - |
Inclusion Criteria: * Histologic or cytologic confirmation of small cell lung cancer * extensive stage disease * adequate pulmonary function tests (FEV-1\>1.0, DLCO\>50%) * patients of childbearing potential must practice adequate contraception * age ≧ 18 years * Karnofsky performance status ≧ 70 *...
Thoracic radiotherapy is used as a consolidative treatment for patients with Extensive Stage Small Cell Lung Cancer. It is delivered to the chest area after initial chemotherapy to target residual disease in the thorax. The goal is to improve local control in this patient population.
Thoracic radiotherapy is being developed by Avalon GloboCare Corp., a biopharmaceutical company traded under the ticker ALBT. The company is conducting clinical research to evaluate this treatment approach in patients with Extensive Stage Small Cell Lung Cancer.
Thoracic radiotherapy is in Phase 2 clinical development. It has completed a Phase 2 trial, which was an uncontrolled, non-randomized study. The treatment is still investigational and has not been approved by regulatory authorities for this indication.
Thoracic radiotherapy has one completed clinical trial, identified as NCT00643396. This Phase 2 trial was titled "Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer" and enrolled 30 participants in Canada. The study included adults aged 18 years and older.
Thoracic radiotherapy is not FDA approved for Extensive Stage Small Cell Lung Cancer. It is an investigational treatment currently in Phase 2 clinical development. The completed trial, NCT00643396, was a single-arm study, and further research would be needed to establish safety and efficacy for regulatory approval.